WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 2, 2018--
Inc. (NASDAQ: BIVV) announced today that it will present at the 2018
J.P. Morgan Healthcare Conference. The event will be webcast live on
Monday, January 8, 2018 at 4:00 p.m. PST. To access the live webcast,
please visit Bioverativ’s Investors page at investors.bioverativ.com.
An archived version of the webcast will be available following the
Bioverativ (NASDAQ: BIVV) is a global
biopharmaceutical company dedicated to transforming the lives of people
with hemophilia and other rare blood disorders through world-class
research, development and commercialization of innovative therapies.
Launched in 2017 following separation from Biogen Inc., Bioverativ
builds upon a strong heritage of scientific innovation and is committed
to actively working with the blood disorders community. The company’s
mission is to create progress for patients where they need it most and
its hemophilia therapies when launched represented the first major
advancements in hemophilia treatment in more than two decades. For more
information, visit www.bioverativ.com
or follow @bioverativ
View source version on businesswire.com: http://www.businesswire.com/news/home/20180102005433/en/
Source: Bioverativ Inc.
Susan Altschuller, Ph.D.,
+1 781 663 4360